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Abstract. The purpose of this study was to examine clinical 
features and treatment modality approaches in patients with 
chronic obstructive pulmonary disease (COPD), particularly 
in those aged 80 years and older. Using databases available at 
Mito Kyodo General Hospital (Japan), the medical records of 
COPD patients between April 2009 and December 2011 were 
retrospectively reviewed. The patient population was divided 
into three age groups; less than 70 years (the <70 age group), 
between 70-79 years (the 70-79 age group) and 80 years or older 
(the ≥80 age group). Demographic data, as well as the efficacy 
and safety of tiotropium, were compared between the three 
groups. Patients in the ≥80 age group comprised 35.6% of the 
study population with COPD (n=174). The ≥80 and 70-79 age 
groups demonstrated a higher proportion of comorbid disease 
compared with the <70 age group. A subjective improvement 
of dyspnea on effort as well as no additional adverse effects 
were observed in the ≥80 age group, similar to the other two 
age groups. However, higher incidence of acute exacerbation of 
COPD in patients aged ≥80 years old was found, particularly 
in those with comorbid disease. The efficacy and safety of 
tiotropium in COPD patients in the ≥80 age group were almost 
identical to patients <80 years old, however, physicians must 
be cautious with acute exacerbation of COPD in the extremely 
elderly population with comorbid disease.
Introduction
In developed countries, populations are becoming older 
with the incidence of respiratory diseases highest amongst 
the elderly (1,2). Among them, the incidence, morbidity and 
mortality of chronic obstructive pulmonary disease (COPD) 
has increased worldwide during the last few decades (1). 
Factors such as recent improvements in the medical 
management of COPD, the availability of new drugs and an 
improved standard of medical care with more widespread 
health services may help to provide favorable treatment 
outcomes. Tiotropium, an agent in a new class of anticholin-
ergics, exhibits a longer duration of action due to prolonged 
muscarinic receptor antagonism (3,4). These effects have 
the therapeutic advantage of making once-daily dosing in 
patients possible (5).
The majority of diagnosed cases of COPD are those 
between the ages of 60 and 80 years, and as a result, there 
are few data relating to the clinical characteristics, disease 
status, treatment modality, efficacy and safety of tiotropium 
treatment in patients aged ≥80 years (6). Too few patients 
>80 years have been included in previous clinical trials to 
allow any significant conclusions with regard to this age group 
to be made. Therefore, additional studies specifically focusing 
on these elderly patients are required. This study reports data 
concerning the efficacy and safety of tiotropium in COPD 
patients, especially in those aged ≥80 years.
Patients and methods
Clinicopathological data. For all consecutive patients with 
COPD, clinicopathological data were obtained by retrospec-
tive review from the databases at the University of Tsukuba, 
Mito Medical Center (Mito Kyodo General Hospital, Japan).
Patients were diagnosed functionally and treated with 
tiotropium (once daily via Respimat 5 µl or HandiHaler® 
18 µg for >4 weeks) between April 2009 and January 2012 
at our hospital. Demographic data, including age, gender and 
comorbid disease, were retrieved from each patient's medical 
record. This study was approved by the Institutional Ethics 
Committee of the Mito Kyodo General Hospital. The entire 
patient population was divided into three age groups; less than 
70 years (the <70 age group), 70-79 years (the 70-79 age group) 
and 80 years or older (the ≥80 age group). Demographic data, 
as well as the efficacy and safety of tiotropium, were compared 
between the three age groups. The efficacy of tiotropium was 
evaluated at 1 month or more from the initiation of the inhala-
tion therapy. Adverse effects were counted as they occurred 
during the study period. Acute exacerbation of COPD was 
defined according to the review by Effing et al (6). Written 
informed patient consent was obtained from each patient.
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Statistical analysis. Differences between the distribution of 
subpopulations between each group were analyzed using the 
Mann-Whitney U test, Kruskal-Wallis test and Chi-square 
test. Statistical significance between paired forced expiratory 
volume in 1 sec (FEV1) levels was evaluated by the Wilcoxon 
signed rank test. All statistical analyses were performed using 
SPSS 10.1 for Windows (SPSS, Inc., Chicaco, IL, USA) and 
P<0.05 was considered to indicate a statistically significant 
result.
Results
Patient characteristics. A total of 174 patients with COPD 
were treated with tiotropium during the study period. Among 
them, 62 patients (35.6%) were ≥80 years (median, 84 years), 
59 patients (33.9%) were between 70-79 years (median, 
75 years) and 53 patients (30.5%) were <70 years (median, 
65 years; Table I). Males constituted 86.2% of the study popu-
lation and the age distribution was comparable between males 
(≥80 years, 34.7%; 70-79 years, 33.3%; <70 years, 32.0%) and 
females (≥80 years, 41.7%; 70-79 years, 37.5%; <70 years, 
20.8%; P=0.5386; Table I). 
Forty-eight of the patients aged ≥80 years (77.4%) had one 
or more comorbid disease, compared with 72.9 and 49.1% of 
patients aged between 70-79 and <70 years old displaying one 
or more comorbid disease, respectively. There was a significant 
difference in the ratio of having one or more comorbid disease 
between those aged ≥70 years and those <70 years (P=0.0009). 
However, no significant difference in the ratio between those 
aged ≥80 years and those <80 years was observed (P=0.5634). 
There was a significant difference in the ratio of having 
prostate disease between those aged ≥70 years and those 
<70 years (P=0.0395), however no significant difference in the 
ratio between those aged ≥80 years and those <80 years was 
observed (P=0.0709).
Treatment of COPD. Treatment and outcome of COPD 
is shown in Table II. Inhaled corticosteroid/long-acting 
β2-agonist (ICS/LABA) was prescribed in 14 (22.6%) patients 
aged ≥80 years, 16 (27.1%) patients aged between 70-79 years 
and 24 (45.3%) patients <70 years. There was a statistically 
significant difference in the ratio between patients ≥70 years 
and those <70 years (P=0.0002). LABA was prescribed in 
15 (24.2%) patients aged ≥80 years, 12 (20.3%) patients aged 
between 70-79 years and 1 (1.9%) patient <70 years. There 
was a statistically significant difference in the ratio between 
patients ≥70 years and those <70 years (P=0.0007). 
Efficacy of tiotropium. After 1 month or longer treatment with 
tiotropium inhalation, subjective improvement of dyspnea on 
effort was observed in 41 (66.1%) patients aged ≥80 years, 43 
(72.9%) patients aged between 70-79 years and 41 (77.4%) 
patients <70 years. There was no statistically significant 
difference in the ratio between patients aged ≥80 years and 
those <80 years (P=0.2128).
Sixty-eight (39.1%) patients had a pulmonary function 
test (PFT) before the initiation of tiotropium treatment and 
FEV1 was 1.14 liters. Only 3 (4.8%) patients aged ≥80 years, 
11 (18.6%) aged between 70-79 years and 19 (35.8%) patients 
<70 years had a respiratory function test prior to tiotropium 
Table I. Characteristics of 174 patients with chronic obstruc-
tive pulmonary disease.
Characteristic Value
Age, n (%): median
  ≥80 years 62 (35.6): 84
  70-79 years 59 (33.9): 75
  <70 years 53 (30.5): 65
Gender, n (%)
  Male 150 (86.2)
  Female 24 (13.8)
Age of patients with comorbid
disease, n (%) 
  ≥80 years 48 (77.4)
  70-79 years 43 (72.9)
  <70 years 26 (49.1)
Age of patients with
prostate disease, n (%) 
  ≥80 years 7 (11.3)
  70-79 years 14 (23.7)
  <70 years 3 (5.7)
Table II. Characteristics of 174 patients with chronic obstruc-
tive pulmonary disease.
Variable  n (%)
Treatment
LABA/ICS
  Aged ≥80 years old 14 (22.6)
  Aged 70-79 years 16 (27.1)
  Aged <70 years 24 (45.3)
LABA
  Aged ≥80 years old 15 (24.2)
  Aged 70-79 years 12 (20.3)
  Aged <70 years 1 (1.9)
Outcome 
  Improvement of symptoms
    Aged ≥80 years old 41 (66.1)
    Aged 70-79 years 43 (72.9)
    Aged <70 years 41 (77.4)
  Admission during the study period 
    Aged ≥80 years old 17 (27.4)
    Aged 70-79 years 3 (5.1)
    Aged <70 years 5 (9.4)
  Adverse effects
    Faintness 1 (0.6)
    Nausea 1 (0.6)
    Arrhythmia 0
    Glaucoma attack 0
    Urinary retention 0
    Dry mouth 0
LABA, long-acting β-agonists; ICS, inhaled corticosteroids.
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therapy and 1-3 months after the initiation of the therapy. Due 
to the small number of patients, improvement of FEV1 was not 
observed in each group of patients (P=0.1088, P=0.0997 and 
P=0.2956, respectively; Wilcoxon signed rank test).
In the patient group aged ≥80 years, 17 (27.4%) patients 
had acute exacerbations of COPD, however, 3 (5.1%) and 5 
(15.2%) patients had the exacerbations in the patient groups 
aged 70-79 years and <70 years, respectively. There was a 
significant difference in the incidence of the exacerbations 
between the most elderly group and the counter groups of 
patients (P=0.0003). In the patient group aged ≥80 years, 14 
(82.4%) patients who experienced the exacerbation had one or 
more comorbid disease.
Safety. Only one (0.6%) patient experienced faintness and 
nausea, respectively. These complaints were observed in 
patients aged between 70-79 years. However, these side-effects 
immediately disappeared after tiotropium inhalation treat-
ment was terminated. During the study period, no patient 
experienced hoarseness, arrhythmia, glaucoma attack, urinary 
retention, dry mouth, constipation, gastrointestinal obstruc-
tion or dysuria. Therefore, an increased incidence of adverse 
effects was not observed in the ≥80 years age group.
Discussion
There has been an increasing interest in the treatment of 
elderly patients with COPD (1,7,8). However, clinical informa-
tion with regard to COPD patients aged ≥80 years has not been 
fully available since such patients are not usually included 
in clinical trials and retrospective care analysis. Therefore, 
a degree of scientific uncertainty regarding the risks and 
benefits of treatment with tiotropium in COPD patients aged 
≥80 years currently exists. We retrospectively reviewed the 
clinical data from consecutive patients with COPD treated 
with tiotropium at our hospital to assess its efficacy and safety 
for treatment in the elderly population. Previous studies have 
reported the efficacy and safety of tiotropium therapy for 
COPD patients (9-11). In these studies, the mean age of the 
patients evaluated were 70.2 years (11), 68.2-69.2 years (9) 
and 65.2 years (10). In our study, the median age of all patients 
was 75 years, and 69.5% of them were ≥70 years old. It is 
noteworthy that the ≥80 age group accounted for 35.6% of all 
our COPD patients. As for FEV1 in previous studies, its mean 
value was 1.02 (9) and 1.17 liters (11). In our study, median 
FEV1 of patients was 1.14 liters. Thus, severity of pulmonary 
function in our patients may be compatible with those in 
previous studies (9,11).
Aging is associated with a higher prevalence of comorbid 
disease (12,13), particularly in those patients with a long 
history of smoking who are predisposed to comorbid 
diseases such as COPD and cardiovascular disease, as well 
as other smoking-related malignancies (14). The ≥80 age 
group had a higher proportion of patients with comorbid 
disease than those in septuagenarians and patients <70 years 
of age. Among them, however, there was a significant differ-
ence in the ratio of having prostate disease between those 
aged ≥70 years and those <70 years, but no difference was 
observed in the ratio between those aged ≥80 years and those 
<80 years. 
In our study, achievement of subjective improvement in 
dyspnea on effort was equivalent in the ≥80 and <80 years 
patient age groups. However, there was a significant difference 
in the incidence of exacerbations between the ≥80 age group 
and the counter groups of patients. One of the reasons may be 
due to the severity of COPD itself as well as that of numerous 
other comorbid diseases in the elderly. Tiotropium inhalation 
is generally well tolerated in patients with COPD, without 
anticholinergic adverse events (e.g. dry mouth, constipation, 
gastrointestinal obstruction, dysuria) (15). Kesten et al reported 
that nasopharyngitis and dry mouth were two of the most 
common adverse events in tiotropium therapy (16). In our study, 
arrhythmia, glaucoma attack, urinary retention, dry mouth, 
constipation, gastrointestinal obstruction and nasopharyngitis 
were not observed, even in the ≥80 age group of patients.
Our results revealed some novel findings, but there were 
a number of limitations in this study. This was a small-sized 
retrospective study in one institution. PFT was not evaluated in 
every patient and quality of life analysis was not performed in 
this study. Therefore, we determined that conclusive outcomes 
were not able to be derived from this study. However, our 
methodology, which was based on an audit of information 
obtained from clinical practice documented in patient records, 
may provide some clinical information which otherwise cannot 
be observed from clinical trials. As numerous elderly patients 
had severe comorbid disease, they were as a result not suitable 
for PFT test, which requires their maxmum effort to perform. 
We believe that reporting the treatment experiences of COPD 
patients, including those elderly patients who cannot perform 
PFT due to complications, is of significance to clinical practice.
The efficacy and safety of tiotropium in COPD patients 
aged ≥80 years was almost identical to that of patients aged 
<80 years, however, physicians must be cautious with acute 
exacerbation of COPD in the extremely elderly population, 
particularly those with comorbid disease.
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